Aligos Therapeutics Inc (ALGS) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Aligos Therapeutics Inc   (NASDAQ: ALGS)


Aligos Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Aligos Therapeutics Inc 's ROA in the second quarter of 2026?
Aligos Therapeutics Inc recorded a cumulative net loss of $-76 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -89.54%.

However, within the Healthcare sector 719 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2026 from 4055 to 4224.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change -43.01 % -57.08 % 26.31 % 23.8 % 23.8 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -76 -90 -24 -86 -74
Return On Assets (TTM) -89.54 % -90.94 % -20.03 % -74.43 % -66.89 %
ALGS's Total Ranking # 4224 # 4055 # 4232 # 4244 # 4163
Total Assets (TTM) in million 77 65 89 109 135
Seq. Total Assets Change 18.92 % -27.08 % -19.13 % -18.73 % -10.45 %
Seq. Net Income Change - - - - -

ALGS's 5 Years Annual ROA >> Back to ALGS Management Effectiveness >> Compare ALGS ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 111
Sector # 720
Overall # 4189

Return On Assets Statistics
High Average Low
-20.01 %
-64.95 %
-132.79 %
(Dec 31 2025)   (Dec 31 2024)



  News about Aligos Therapeutics Inc Return on Assets ROA

Aligos Therapeutics Strengthens Leadership and Reports Breakthrough Advances in MASH Treatment Amidst Market Challenges

In a significant strategic move reflecting its commitment to advancing therapeutic interventions for liver diseases, Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical-stage biopharmaceutical company based in South San Francisco, has appointed David Perry as Vice President of Business Development, effective immediately. Perry’s extensive background in the biopharmaceutical sector, combined with his keen insight into market dynamics, positions him to play a crucial role in navigating the evolving landscape of therapeutic development and commercial engagement for the company.This appointment comes on the heels of encouraging developments in Aligos’s clinical portfolio, particularly the promising topline results reported from the Phase 2a HERALD study, which evaluates ALG-055009, a novel thyroid hormone receptor beta (THR-?) agonist. Announced on September 19, 2024, the results spotlight the potential of ALG-055009 in treating metabolic dysfunction-associated steatohepatitis, known as MASH—a condition that has emerged as a significant public health concern due to the rising prevalence of obesity and metabolic syndrome.



Financial Statements
Aligos Therapeutics Inc 's Assets $ 77 million ALGS's Balance sheet
Aligos Therapeutics Inc 's Income $ -2 million Quarterly ALGS's Income Statement
ALGS's Income by Division See ALGS's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 26.31 % -53.69 % 3.17 % -37.68 % -11.19 %
Total Assets in million 89 70 151 147 235
Y / Y Net Income Change - - - - -
Net Income in million -24 -131 -88 -96 -128
Annual Return On Assets -27.33 % -187.19 % -57.93 % -65.47 % -54.52 %

ALGS's 5 Years Annual ROA >> Back to ALGS Management Effectiveness >> Compare ALGS ROA to its Competitors



More Return On Assets Ratios
ALGS's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ALGS's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ALGS's Competitors
Subscribers only: Roa for Aligos Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for ALGS's Customers

You may also want to know
ALGS's Roi ALGS's Inventory Turnover Ratio ALGS's Growth Rates ALGS's Dividend Comparisons
ALGS's Profitability Ratios ALGS's Asset Turnover Ratio ALGS's Dividend Growth
ALGS's Roe ALGS's Valuation Ratios ALGS's Financial Strength Ratios ALGS's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA

Date modified: 2026-09-08T10:47:16+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.